Week in Review: Shanghai Hansoh Enters $68 Million Deal For Leukemia Candidate
August 01, 2020 at 14:34 PM EDT
Shanghai Hansoh Pharma obtained Greater China rights to a BCR-ABL inhibitor discovered by Terns Pharma of California. Hansoh will make an upfront payment, plus milestones of up to $68 million. It will also pay royalties on sales.
